• 1
    Ingram GI. The history of haemophilia. J Clin Pathol 1976; 29: 46979.
  • 2
    James P, Coller B. Phenotyping bleeding. Curr Opin Hematol 2012; 19: 40612.
  • 3
    Ajani U, Ford E, Greenland K, Giles W, Mokdad A. Aspirin use among U.S. adults: behavioral risk factor surveillance system. Am J Prev Med 2006; 30: 747.
  • 4
    Filippi A, Bianchi C, Parazzini F, Cricelli C, Sessa E, Mazzaglia G. A national survey on aspirin patterns of use and persistence in community outpatients in Italy. Eur J Cardiovasc Prev Rehabil 2011; 18: 695703.
  • 5
    Liotta EM, Prabhakaran S. Warfarin-associated intracerebral hemorrhage is increasing in prevalence in the United States. J Stroke Cerebrovasc Dis 2012; doi: 10.1016/j.jstrokecerebrovasdis.2012.11.015.
  • 6
    Rodeghiero F, Michel M, Gernsheimer T, Ruggeri M, Blanchette V, Bussel JB, Cines DB, Cooper N, Godeau B, Greinacher A, Imbach P, Khellaf M, Klaassen RJ, Kühne T, Liebman H, Mazzucconi MG, Newland A, Pabinger I, Tosetto A, Stasi R. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood 2013; 121: 2596606.
  • 7
    Beyth R, Quinn L, Landefeld C. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 919.
  • 8
    Beyth R, Quinn L, Landefeld C. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med 2000; 133: 68795.
  • 9
    Landefeld C, Anderson P, Goodnough L, Moir T, Hom D, Rosenblatt M, Goldman L. The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy. J Clin Epidemiol 1989; 42: 7118.
  • 10
    Landefeld C, Beyth R. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. The American Journal of Medicine 1993; 95: 31528.
  • 11
    Landefeld C, McGuire E, Rosenblatt M. A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy. The American Journal of Medicine 1990; 89: 56978.
  • 12
    Graafsma Y, Prins M, Lensing A, de Haan R, Huisman M, Büller H. Bleeding classification in clinical trials: observer variability and clinical relevance. Thromb Haemost 1997; 78: 118992.
  • 13
    Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8: 2024.
  • 14
    Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 6924.
  • 15
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; Committee R-LS, Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 113951.
  • 16
    The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 23341.
  • 17
    Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293304.
  • 18
    Gaist D, Wallander MA, Gonzalez-Perez A, Garcia-Rodriguez LA. Incidence of hemorrhagic stroke in the general population: validation of data from The Health Improvement Network. Pharmacoepidemiol Drug Saf 2013; 22: 17682.
  • 19
    Daniel WW. Biostatistics: A Foundation for Analysis in the Health Science. New York: Wiley, 1987.
  • 20
    Mauser Bunschoten EP, van Houwelingen JC, Sjamsoedin Visser EJ, van Dijken PJ, Kok AJ, Sixma JJ. Bleeding symptoms in carriers of hemophilia A and B. Thromb Haemost 1988; 59: 34952.
  • 21
    Quiroga T, Goycoolea M, Panes O, Aranda E, Martinez C, Belmont S, Munoz B, Zuniga P, Pereira J, Mezzano D. High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. Haematologica 2007; 92: 35765.
  • 22
    von Silwer J. Willebrand's disease in Sweden. Acta Paediatr Scand Suppl 1973; 238: 1159.
  • 23
    Sramek A, Eikenboom JC, Briet E, Vandenbroucke JP, Rosendaal FR. Usefulness of patient interview in bleeding disorders. Arch Intern Med 1995; 155: 140915.
  • 24
    Wahlberg T, Blomback M, Hall P, Axelsson G. Application of indicators, predictors and diagnostic indices in coagulation disorders. I. Evaluation of a self-administered questionnaire with binary questions. Methods Inf Med 1980; 19: 194200.
  • 25
    Mauer A, Khazanov N, Levenkova N, Tian S, Barbour E, Khalida C, Tobin J, Coller B. Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults. J Thromb Haemost 2011; 9: 1008.
  • 26
    Webert K, Cook R, Couban S, Carruthers J, Heddle N. A study of the agreement between patient self-assessment and study personnel assessment of bleeding symptoms. Transfusion 2006; 46: 192633.
  • 27
    Quiroga T, Mezzano D. Is my patient a bleeder? A diagnostic framework for mild bleeding disorders. Hematology Am Soc Hematol Educ Program 2012; 2012: 46674.
  • 28
    Rodeghiero F, Tosetto A, Castaman G. How to estimate bleeding risk in mild bleeding disorders. J Thromb Haemost 2007; 5(Suppl. 1): 15766.
  • 29
    Castaman G, Tosetto A, Federici AB, Rodeghiero F. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance. Thromb Haemost 2011; 105: 64754.
  • 30
    Castaman G, Federici AB, Tosetto A, La Marca S, Stufano F, Mannucci PM, Rodeghiero F. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost 2012; 10: 6328.
  • 31
    Sadler JE, Rodeghiero F. Provisional criteria for the diagnosis of VWD type 1: on behalf of the ISTH SSC Subcommittee on von Willebrand Factor. J Thromb Haemost 2005; 3: 7757.
  • 32
    Rodeghiero F, Castaman G, Tosetto A, Batlle J, Baudo F, Cappelletti A, Casana P, De Bosch N, Eikenboom JC, Federici AB, Lethagen S, Linari S, Srivastava A. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2005; 3: 261926.
  • 33
    Tosetto A, Castaman G, Plug I, Rodeghiero F, Eikenboom J. Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation. J Thromb Haemost 2011; 9: 11438.
  • 34
    Elden L, Reinders M, Witmer C. Predictors of bleeding disorders in children with epistaxis: value of preoperative tests and clinical screening. Int J Pediatr Otorhinolaryngol 2012; 76: 76771.
  • 35
    Bernardi F, Dolce A, Pinotti M, Shapiro A, Santagostino E, Peyvandi F, Batorova A, Lapecorella M, Schved J, Ingerslev J, Mariani G, International Factor VIIDSG. Major differences in bleeding symptoms between factor VII deficiency and hemophilia B. J Thromb Haemost 2009; 7: 7749.
  • 36
    van Dijk K, Fischer K, van der Bom J, Grobbee D, van den Berg H. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia 2005; 11: 43843.
  • 37
    Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Hoffmann RG, Montgomery RR. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman program for the molecular and clinical biology of VWD. Blood 2011; 117: e6774.
  • 38
    James PD, Notley C, Hegadorn C, Leggo J, Tuttle A, Tinlin S, Brown C, Andrews C, Labelle A, Chirinian Y, O'Brien L, Othman M, Rivard G, Rapson D, Hough C, Lillicrap D. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007; 109: 14554.
  • 39
    Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, Meyer D, Fressinaud E, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4: 76673.
  • 40
    Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, Neunert C, Lillicrap D, ISTH SSC joint VWF Perinatal/Pediatric Hemostasis Subcommittees Working Group. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010; 8: 20635.
  • 41
    Rydz N, James PD. The Evolution and value of bleeding assessment tools. J Thromb Haemost 2012; 10: 22239.
  • 42
    Tosetto A, Castaman G, Rodeghiero F. Assessing bleeding in von Willebrand disease with bleeding score. Blood Rev 2007; 21: 8997.
  • 43
    Tosetto A, Castaman G, Rodeghiero F. Bleeding scores in inherited bleeding disorders: clinical or research tools? Haemophilia 2008; 14: 41522.
  • 44
    O'Brien SH. Bleeding scores: are they really useful? Hematology Am Soc Hematol Educ Program 2012; 2012: 1526.
  • 45
    Bidlingmaier C, Grote V, Budde U, Olivieri M, Kurnik K. Prospective evaluation of a pediatric bleeding questionnaire and the ISTH bleeding assessment tool in children and parents in routine clinical practice. J Thromb Haemost 2012; 10: 133541.
  • 46
    Bowman M, Mundell G, Grabell J, Hopman WM, Rapson D, Lillicrap D, James P. Generation and validation of the condensed MCMDM-1VWD bleeding questionnaire for von Willebrand disease. J Thromb Haemost 2008; 6: 20626.
  • 47
    Bowman M, Riddel J, Rand ML, Tosetto A, Silva M, James PD. Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. J Thromb Haemost 2009; 7: 141821.
  • 48
    Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, Meyer D, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Lethagen S, Hill FG, Peake I. A comparison between two semi-quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease. Haemophilia 2011; 17: 1656.
  • 49
    Mauer AC, Barbour EM, Khazanov NA, Levenkova N, Mollah SA, Coller BS. Creating an ontology-based human phenotyping system: the Rockefeller University bleeding history experience. Clin Transl Sci 2009; 2: 3825.
  • 50
    ISTH Bleeding Assessment Tool Standing Committee. Accessed 24 January 2013.
  • 51
    Rodeghiero F, Castaman G, Tosetto A. How I treat von Willebrand disease. Blood 2009; 114: 115865.
  • 52
    Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 2012; 60: 8617.
  • 53
    Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012; 33: 150010.
  • 54
    Olesen JB, Lip GY, Hansen PR, Lindhardsen J, Ahlehoff O, Andersson C, Weeke P, Hansen ML, Gislason GH, Torp-Pedersen C. Bleeding risk in ‘real world’ patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost 2011; 9: 14607.
  • 55
    Roldan V, Marin F, Fernandez H, Manzano-Fernandez S, Gallego P, Valdes M, Vicente V, Lip GY. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a ‘real world’ anticoagulated atrial fibrillation population. Chest 2013; 143: 17984.
  • 56
    Scherz N, Mean M, Limacher A, Righini M, Jaeger K, Beer HJ, Frauchiger B, Osterwalder J, Kucher N, Matter CM, Banyai M, Angelillo-Scherrer A, Lammle B, Husmann M, Egloff M, Aschwanden M, Bounameaux H, Cornuz J, Rodondi N, Aujesky D. Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism. J Thromb Haemost 2013; 11: 43543.
  • 57
    Federici AB, Bucciarelli P, Castaman G, Mazzucconi MG, Morfini M, Rocino A, Schiavoni M, Rodeghiero F, Mannucci PM. Incidence and determinants of bleeding in different types of von Willebrand disease: results of the first prospective multicenter study on 814 Italian patients. Blood (ASH Annual Meeting Abstracts) 2007; 110: Abstract 713
  • 58
    Tosetto A, Castaman G, Rodeghiero F. Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. Blood 2008; 111: 39984003.
  • 59
    Astermark J, Negrier C, Hermans C, Holme PA, Klamroth R, Kotsi P, de Moerloose P, Pasi J, Rocino A, von Depka M, Windyga J, Ludlam CA. European curriculum for thrombosis and haemostasis. Haemophilia 2009; 15: 33744.
  • 60
    National Center for Biomedical Ontology. Accessed 24 January 2013.
  • 61
    Knight C, Paisley S, Wight J, Jones M. Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia 2003; 9: 52140.